drugset / Trial / NCT01259128

Study to Investigate the Safety and Pharmacokinetics of SER120 Nasal Spray in Elderly Patients With Nocturia

NCT01259128

Phase 3 Completed 32 enrolled Serenity Pharmaceuticals, Inc.
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if SER120 nasal spray is well tolerated in 75 years or older nocturic patients.

Timeline

Start
2010-04
Primary completion
2010-11
Completion
2010-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Desmopressin Peptide 500 ng Intranasal
Subject Desmopressin Peptide 750 ng Intranasal

Indications